Nasdaq
$32.20▲ 0.62%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.10BShares out 2.800M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 9.23After-hours26.09.24 06:064Ownership#●●●
Caris Life Sciences, Inc.
Insider Denton John Russel of Caris Life Sciences, Inc. reported a change in beneficial ownership of securities as of September 22, 2026. This filing is a standard disclosure of insider transactions regarding the company's equity structure.…more
$32.20+0.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 05:08144Ownership
Caris Life Sciences, Inc.
Insider Denton John Russel of Caris Life Sciences, Inc. has filed an SEC Form 144 to report a proposed sale of company securities. This filing serves as a formal notification of the insider's plan to dispose of their holdings.…more
$32.20+0.62%vs prev closeView filingShare - 9.17After-hours26.09.18 07:084Ownership
Caris Life Sciences, Inc.
Insider Brian J. Brille of Caris Life Sciences, Inc. filed a Form 4 on September 17, 2026, reporting a change in beneficial ownership of securities. This filing serves as an official disclosure of the insider's equity transaction to the SEC.…more
$32.20+0.62%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.27Pre-market26.08.27 21:35#●●●#●●●
Caris Life Sciences Publishes AI-Driven Pancreatic Cancer Treatment Study…more
Caris Life Sciences has published a study validating an AI-driven approach to selecting first-line treatments for pancreatic cancer. The research demonstrates that AI-based molecular signatures can improve treatment selection, potentially enhancing patient survival and reducing toxicity.…more
$32.20+0.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga